@Article{Sobow2007,
journal="Archives of Medical Science",
issn="1734-1922",
volume="3",
number="1",
year="2007",
title="Short communication Cholinesterase inhibitors for Parkinson\’s disease-related visual hallucinations unresponsive to atypical antipsychotics",
abstract="Introduction: Considering lack of accepted guideline in cases of Parkinson\’s disease-related visual hallucinations with poor response or intolerance to antipsychotics, and their possible cholinergic pathogenesis, the trial with cholinesterase inhibitors seems to be legitimated. Material and methods: Five patients with PD (with or without dementia) complicated by VH and unresponsive to atypical antipsychotics were offered  a 12-week, open-label trial of a cholinesterase inhibitor.  Results: All 5 subjects completed the trial with no major adverse effects and, noteworthy, no discontinuations due to adverse events. VH resolved in 4 subjects and were markedly diminished in one person. Neither changes in UPDRS scores nor exaggeration of subjective complaints about extrapyramidal symptoms were noted during treatment.  Conclusions: Cholinesterase inhibitors, rivastigmine or donepezil, might represent a useful alternative to antipsychotics for patients with PD accompanied by VH even in the absence of dementia.",
author="Sobow, Tomasz",
pages="69--72",
url="https://www.termedia.pl/Short-communication-Cholinesterase-inhibitors-for-Parkinson-8217-s-disease-related-visual-hallucinations-unresponsive-to-atypical-antipsychotics,19,7868,1,1.html"
}